Tag:
Pfizer
Latest Headlines
Latest Headlines
UPDATED: Pfizer recalled 653,000 bottles of smelly Advil
In March, the company pulled more than 650,000 bottles of Advil gel tabs from stores because because they had a strong odor, according to a notice on the FDA website.
Even some domestic firms rail at India's price control plan
India's plan to again put price controls on the majority of the drugs in the country has become a flash point for companies there as well as Western drugmakers.
Pfizer's targeted drug knocks out child cancers in small study
Some of the biggest headlines coming out of the massive ASCO abstract release aren't focused on a promising experimental treatment. They're about Pfizer's recently approved treatment Xalkori.
Study links Z-Pak with risk of sudden death
The commonly used Pfizer antibiotic Zithromax, also known as Z-Pak, may increase the risk of sudden death in adults.
Pfizer's targeted drug knocks out child cancers in small study
Xalkori was tested in children with rare cancers, and its success illustrates how targeted drugs can progress beyond their initial uses.
UPDATED: ASCO abstracts reveal added appeal for key cancer drug prospects
The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.
Pfizer making deep cuts at estrogen extraction plant
Pfizer ($PFE), which faces thousands of lawsuits over hormone replacement therapies, will cut about 40% of the workforce at a Canadian plant where one of them is made.
Cancer drug experts brace for ASCO abstract dump tonight
ASCO is releasing a mountain of data on cancer studies, and some of the biggest names in the business will be angling for star billing on some closely watched therapies.
Payers likely to throw up hurdles to Pfizer's new RA drug
You know that old adage: The one with the gold makes the rules? For the latest exhibit, look no further than Pfizer's anticipated rheumatoid arthritis treatment tofacitinib.
Payers likely to throw up hurdles to Pfizer's new RA drug
The FDA may be a new drug's biggest hurdle, but payers are throwing up more obstacles as high-tech treatments get pricier and healthcare costs keep rising.
